Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsSteven Aronin, MD, FACP
Associate Clinical ProfessorAbout
Research
Publications
2025
Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection.
Puttagunta S, Aronin S, Gupta J, Das A, Gupta K, Dunne M. Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection. NEJM Evidence 2025, 4: evidoa2400414. PMID: 40552968, DOI: 10.1056/evidoa2400414.Peer-Reviewed Original ResearchConceptsUrinary tract infectionUncomplicated urinary tract infectionsIntent-to-treat populationSusceptible to amoxicillin/clavulanateTract infectionsUrine cultureAdverse eventsTreatment of uncomplicated urinary tract infectionsCombined population of patientsPatients treated with amoxicillin/clavulanateTreatment-emergent adverse eventsBaseline urine culturePositive urine cultureMild adverse eventsPopulation of patientsTreatment of adult womenClasses of antibioticsMicrobiological eradicationBaseline pathogensClinical cureDouble-blindMedian ageTrial medicationAmoxicillin/clavulanateAntimicrobial resistanceIn vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023
Aronin S, Huband M, Becker H, Fedler K, Dunne M. In vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023. Journal Of Global Antimicrobial Resistance 2025, 44: 152-159. PMID: 40555323, DOI: 10.1016/j.jgar.2025.06.013.Peer-Reviewed Original ResearchEnterobacterales clinical isolatesUrinary tract infectionIn vitro activityClinical isolatesEnterobacterales isolatesTract infectionsComparator agentsCLSI broth microdilution reference methodBroth microdilution reference methodSENTRY Antimicrobial Surveillance ProgramTreat urinary tract infectionsResistance phenotypeIsolates non-susceptibleMicrodilution reference methodAntimicrobial Surveillance ProgramOral antimicrobial agentsUS medical centersTreatment of womenUrinary isolatesInfection typeNon-susceptibilityOral formulationClinical evaluationUS FDABacterial infectionsCharacterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates
Maher J, Huband M, Lindley J, Rhomberg P, Aronin S, Puttagunta S, Castanheira M. Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates. Microbiology Spectrum 2025, 13: e01898-24. PMID: 39907459, PMCID: PMC11878024, DOI: 10.1128/spectrum.01898-24.Peer-Reviewed Original ResearchConceptsUncomplicated urinary tract infectionsPost-antibiotic effectIntra-abdominal infectionsTreatment of urinary tractTime-kill testsMultidrug-resistant pathogensBaseline MICPenem antibioticUrinary tractPAE effectsClinical developmentBroth microdilution susceptibility testingPhase 3 clinical trialsKlebsiella pneumoniae isolatesOral dosing regimenUrinary tract infectionMicrodilution susceptibility testingPAE-SMETime-kill assayTime-kill kineticsStudy evaluated inMg/500 mgAmoxicillin-clavulanateTract infectionsSusceptibility testing
2024
A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections
Dunne M, Aronin S, Das A, Akinapelli K, Breen J, Zelasky M, Puttagunta S. A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections. Clinical Microbiology And Infection 2024, 31: 396-401. PMID: 39491784, DOI: 10.1016/j.cmi.2024.10.025.Peer-Reviewed Original ResearchComplicated intraabdominal infectionsIntraabdominal infectionsPhase 3 randomized trialErtapenem-treated patientsClinical success rateRandomized to 5Confidence intervalsNon-inferiority marginOral regimensAmoxicillin-clavulanateClinical responsePrimary endpointTreatment armsIsolated pathogensTreatment durationHospitalized adultsErtapenemB. fragilisPatientsSuccess rateSulopenemInfectionEndpointTreatment differencesDays